| Literature DB >> 30305106 |
Mathieu V Paulin1, Lucile Couronné2,3,4, Jérémy Beguin5, Sophie Le Poder6, Maxence Delverdier7, Marie-Odile Semin7, Julie Bruneau8,9, Nadine Cerf-Bensussan3,10, Georgia Malamut11,12, Christophe Cellier11,12, Ghita Benchekroun5, Laurent Tiret13, Alexander J German14, Olivier Hermine2,3,4, Valérie Freiche15.
Abstract
BACKGROUND: Low-grade alimentary lymphoma (LGAL) is characterised by the infiltration of neoplastic T-lymphocytes, typically in the small intestine. The incidence of LGAL has increased over the last ten years and it is now the most frequent digestive neoplasia in cats and comprises 60 to 75% of gastrointestinal lymphoma cases. Given that LGAL shares common clinical, paraclinical and ultrasonographic features with inflammatory bowel diseases, establishing a diagnosis is challenging. A review was designed to summarise current knowledge of the pathogenesis, diagnosis, prognosis and treatment of feline LGAL. Electronic searches of PubMed and Science Direct were carried out without date or language restrictions.Entities:
Keywords: Cat; Comparative oncology; Human indolent digestive T-cell lymphoproliferative disorder; Inflammatory bowel disease
Mesh:
Year: 2018 PMID: 30305106 PMCID: PMC6180644 DOI: 10.1186/s12917-018-1635-5
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Comparison of aetiology, epidemiology, and clinical features in cats with low-grade alimentary lymphoma (LGAL) and inflammatory bowel diseases (IBD)
| LGAL | IBD | |
|---|---|---|
| Aetiology | Currently unknown | Currently unknown, multifactorial disease, though many factors implicated including genetic factors and enteric bacteria or protozoa [ |
| Age | Mainly older cats [ | Any age [ |
| Breed | No breed predisposition [ | Domestic shorthair and longhair, Persian, Siamese predisposed [ |
| Gastrointestinal locations | Any but jejunum and ileum most common (90%) [ | Any but duodenum and ileum most common (70–90%) [ |
| Clinical signs | Weight loss, vomiting, anorexia, diarrhea, lethargy [ | Weight loss, vomiting, anorexia, diarrhea, lethargy [ |
| Biomarkers | ||
| Albumin | Decreased (49%) | Decreased (77%) [ |
| Total proteins | NA | Increased (18%) [ |
| Cobalamin | Decreased (50–80%) [ | Decreased (18–47%) [ |
| Folate | Increased (37%) [ | Increased (22%) [ |
| LDH | Increased (47%) [ | Increased (26%) [ |
| ALP and ALT | NA | Increased (23%) [ |
| fPLI | NA | Increased (18%) [ |
| Phosphate | NA | Decreased (47%) [ |
| Ultrasonography | Muscularis propria frequently thickened [ | Muscularis propria frequently thickened in eosinophilic enteritis (EE), and occasionally in lymphoplasmacytic enteritis (LPE) [ |
| Histological features and immunohistochemistry | Diffuse infiltration by monomorphic neoplastic T-cells [ | Polymorphic inflammatory infiltrate of lymphocytes, plasma cells (LPE), neutrophils, eosinophils (EE), and macrophages [ |
| Clonality test | Clonal population of lymphocytes [ | Polyclonal population of lymphocytes [ |
NA not available
Segments of the gastrointestinal tract affected by low-grade alimentary lymphoma (LGAL)
| Segments of the small intestine | Prevalence | Study |
|---|---|---|
| Duodenum | 83% (10/12) | Lingard et al. [ |
| Jejunum | 100% (15/15) | Lingard et al. [ |
| 86% (43/50) | Fondacaro et al. [ | |
| Ileum and ileocaecocolic junction | 93% (13/14) | Lingard et al. [ |
Description and prevalence of paraclinical data abnormalities reported in alimentary lymphoma (AL)
| Data | Description | Paraclinical data | AL | |
|---|---|---|---|---|
| Cases | Prevalence | |||
| Albumin | Biomarker of gastrointestinal protein loss [ | Decreased [ | LGAL | 49% (21/43) [ |
| Cobalamin (Vitamin B12) | Biomarker of absorption [ | Decreased [ | LGAL | 50–80% [ |
| AL | 35,3% (6/17) whose 12 LGAL [ | |||
| Folate (Vitamin B9) | Biomarker of absorption and dysbiosis [ | Increased or decreased [ | LGAL | 37% (10/27) > 21.6 ng/ml [ |
| AL | 31% (4/13) < 9.7 ng/ml [ | |||
| Lactate dehydrogenase (LDH) | Biomarker of cellular necrosis [ | Increased [ | LGAL | 47% (9/19) [ |
| Fecal a1 proteinase inhibitor concentration | Biomarker of gastrointestinal protein loss [ | Increased [ | AL | 100% (8/8) [ |
| Total serum protein | Biomarker of gastrointestinal protein loss [ | Decreased [ | AL | 100% (7/7) [ |
Fig. 1Ultrasonographic appearance of normal intestine (a) and low-grade alimentary lymphoma (LGAL) (b), longitudinal section. Note the marked thickening of the muscularis propria in the patient with LGAL (b) compared to a cat with a normal jejunal layering (a). The full thickness of both loops (between calipers) is within normal limits: normal jejunum 2.7 mm and LGAL jejunum 2.5 mm. Scale: 10 mm
Fig. 2Ultrasonographic images depicting a diffuse intestinal wall thickening in low-grade alimentary lymphoma (LGAL) (a) and inflammatory bowel disease (IBD) (b). a Cat with advanced LGAL (duodenum): a moderate thickening of the muscularis propria is observed. Full-thickness (between calipers): 3.7 mm. b Cat with IBD, eosinophilic enteritis (small intestine): note the similar ultrasonographic appearance of the intestine compared to LGAL aspect. Full thickness (between calipers): 3.9 mm. Scale: 10 mm
Comparison of ultrasonographic features observed in low-grade alimentary lymphoma (LGAL) and inflammatory bowel disease (IBD)
| Ultrasonographic parameter | LGAL | IBD |
|---|---|---|
| Gastrointestinal wall thickness | Muscularis propria frequently thickened [ | Muscularis propria frequently thickened in eosinophilic enteritis (EE), possibly increased in lymphoplasmacytic enteritis (LPE) [ |
| Size of mesenteric lymph nodes | Lymphadenomegaly (> 5 mm) frequent but not systematic [ | Lymphadenomegaly frequent but not systematic [ |
| Gastrointestinal intramural masses | Rare but possible [ | Rare but possible [ |
| Stratification and architecture | Normal [ | Normal to modified [ |
| Motility | Normal to reduced [ | Normal to reduced [ |
| Intussusception | Rare but possible [ | Very rare but possible [ |
| Liver appearance | Hypo- or hyperechogenicity possible, lobular pattern if liver involved [ | Non specific [ |
| Pancreas | NA | Changes suggestive of pancreatitis (pancreatic hypoechogenicity, peripancreatic hyperechoic fat) [ |
NA not available
Fig. 3Histological features of low-grade alimentary lymphoma (LGAL) and plasmacytic enteritis (haematoxylin-eosin-staining, 400X). a LGAL: monomorphic dense infiltrate of small lymphocytic cells with discrete nuclear atypia; some plasma cells are present. b Plasmacytic enteritis: less compact infiltrate of small lymphocytes with dense nucleus; more plasma cells are present
Fig. 4Histological (a) (haematoxylin-eosin-staining, 200X) and immunohistochemical (b) (anti-CD3, immunoperoxydase, 200X) features of low-grade alimentary lymphoma (LGAL) showing dense infiltration of the lamina propria composed of a mixture of small CD3+ T lymphocytes and plasma cells, with epitheliotropism (small intestine biopsies)
Description of chemotherapy protocols based on Chlorambucil (PO) and Prednisolone (PO) administration in low-grade alimentary lymphoma (LGAL) [20, 59, 72, 97]
| Study | Stein et al. [ | Lingard et al. [ | Kiselow et al. [ | Fondacaro et al. [ |
|---|---|---|---|---|
| Number of cases | 28 | 12 | 41 | 29 |
| Prednisolone | 1–2 mg/kg PO q24hb | 3 mg/kg PO q24h, tapering to 1–2 mg/kg once in remission | 5 mg/cat PO q12-24 h | 10 mg/cat PO/cat/day |
| Chlorambucil | 20 mg/m2 PO q2wkc | 15 mg/m2 PO q24h for 4d q3wk | 2 mg/cat PO q48h | 15 mg/m2 PO q24h for 4d q3wkd |
| Number responding | 27 (96%) | NA | 37 (95%) | NA |
| Complete remission rate | NA | NA | 22 (56%) | 20 (69%) |
| Median remission timea | 786 days | 505 days | 897 days | 615 days |
| Median survival time | NA | 513 days | 704 days | 510 days |
NA not available
aRemission time in days for cats displaying a complete response; bTwo cats received dexamethasone, initially at immunosuppressive dosages and then at dosages that were gradually tapered over the course of 3 weeks; cBecause of client preference, two cats were switched to 20 mg/m2 chlorambucil orally q3wk; dTwelve of the 20 cats that achieved CR received cyclophosphamide 225 mg/m2 PO q3wk, once they were out of remission
Pathological features of human digestive T-cell lymphoma [25, 153, 164, 165, 175, 176]
| Clinical features | Histology | Immunophenotype | Outcome | |
|---|---|---|---|---|
| Indolent digestive T-cell lymphoproliferative disease | Diarrhoea, abdominal pain | - Crypt hyperplasia, variable degrees of villous atrophy | CD3+, CD8+ or CD4+, CD2+, CD5+/−, CD7+/−, CD30-, CD56-, TCRαβ+ | Indolent chronic relapsing course |
| Enteropathy associated T-cell lymphoma (EATL) | Overt or silent gluten-sensitive enteropathy | - Crypt hyperplasia, villous atrophy | CD3+, CD5-, CD8−/+, CD56-, CD103+, often CD30+, cytotoxic phenotype +/−, TCR αβ + (usually) | Aggressive |
| Monomorphic epitheliotropic T-cell lymphoma | Occurs without a history of coeliac disease | - No crypt hyperplasia, possible villous atrophy | CD3+, CD5-, CD4-, CD8+, CD56+, cytotoxic phenotype, CD30-, TCR γδ + (usually) | Aggressive |
Comparison of feline low-grade alimentary lymphoma (LGAL) and human indolent digestive T-cell lymphoproliferative disease (LPD)
| Data | Feline LGAL | Human indolent digestive T-cell LPD |
|---|---|---|
| Epidemiology | Frequent, increasing prevalence over the last decade | Very rare |
| Clinical signs | Non-specific weight loss, vomiting, anorexia, diarrhoea | Non-specific weight loss, diarrhoea, abdominal pain, digestive bleeding, malnutrition |
| Gastrointestinal localisation | Multiple lesions affecting all the gastrointestinal tract; small intestine as main involvement | Multiple lesions affecting all the gastrointestinal tract; small intestine as main involvement |
| Histology | Monomorphic population of small- to intermediate-sized T-lymphocytes; infiltration of neoplastic T-cells in villi and lamina propria; moderate villous atrophy; crypt hyperplasia | Monomorphic population of small- to intermediate-sized T-lymphocytes |
| Immunophenotyping | CD3+ | CD3+ CD4+ (frequent) |
| Clonality pattern | Clonal or oligoclonal TCRγ rearrangement | Clonal or oligoclonal TCRγ rearrangement |
| Main differential diagnosis | Inflammatory bowel disease | Refractory coeliac disease, autoimmune enteropathy |
| Outcome | Indolent evolution | Indolent evolution |
| Median survival time of 2 years | Persistent disease at a median follow up of 5 years | |
| Treatment | No gold standard | No gold standard |
| Chlorambucil and steroids most common | “Watch and wait” strategy, immunosuppressive agents, chemotherapy (CHOP regimen), anti CD52 monoclonal antibody |
Fig. 5Comparison of histological and immunohistochemical features of feline low-grade alimentary lymphoma (LGAL) and human indolent digestive T-cell lymphoproliferative disease (LPD). Top Panel: Human indolent CD4+ T-cell lymphoproliferative disease of the gastrointestinal tract. Biopsies of the antrum (a, b, c) and duodenum (d, e, f) show important CD3+ (b and e) and CD4+ (c and f) lymphoid infiltrate into the lamina propria (asterisk), mostly composed by small lymphocytes. Epitheliotropism is mostly absent, with however focal exceptions such as small CD4+ T-cells localized here in the duodenal epithelium (arrow). Bottom Panel: Feline T-cell low-grade alimentary lymphoma. Biopsies of the jejunum show epitheliotropic lymphocytic infiltrate involving the lamina propria (g), exhibiting a CD3+ phenotype (h)